Shares of Immatics N.V. (NASDAQ:IMTX – Get Free Report) saw unusually-high trading volume on Thursday . TD Cowen began coverage on shares of Immatics in a research report on Tuesday, April 28th. Wall Street Zen lowered Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings downgraded Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Immatics Company Profile(Get Free Report)Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors.